Proteomic signatures of serum albumin-bound proteins from stroke patients with and without endovascular closure of PFO are significantly different and suggest a novel mechanism for cholesterol efflux

Clinical Proteomics

Volumn 12, Issue 1, 2015, Pages

  Lopez, Mary F ^a   Krastins, Bryan ^a   Sarracino, David A ^a   Byram, Gregory ^a   Vogelsang, Maryann S ^a   Prakash, Amol ^a   Peterman, Scott ^a   Ahmad, Shadab ^a   Vadali, Gouri ^a   Deng, Wenjun ^b   Inglessis, Ignacio ^b   Wickham, Tom ^b   Feeney, Kathleen ^b   Dec, G William ^b   Palacios, Igor ^b   Buonanno, Ferdinando S ^b   Lo, Eng H ^b   Ning, Mingming ^b  

^a Thermo Scientific BRIMS ^*  (United Kingdom)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Albumin; Biomarker; Cerebrovascular disease; Discovery; Ischemic stroke; Mass spectrometry; Patent foramen ovale; PFO; Proteomics; Stroke

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; KININOGEN; SERUM ALBUMIN; VITAMIN D BINDING PROTEIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; COLORIMETRY; ENDOVASCULAR SURGERY; FEMALE; HEART PROTECTION; HUMAN; LIPID OXIDATION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MIDDLE AGED; PATENT FORAMEN OVALE; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEOMICS; STROKE PATIENT;

EID: 84921866511     PISSN: 15426416     EISSN: 15590275     Source Type: Journal    
DOI: 10.1186/1559-0275-12-2     Document Type: Article

References (40)

1. Ning M, Lo EH, Ning PC, Xu SY, McMullin D, Demirjian Z: The brain's heart - therapeutic opportunities for patent foramen ovale (PFO) and neurovascular disease. Pharmacol Ther 2013, 139:111-23. 10.1016/j.pharmthera.2013.03.007
2. Inglessis I, Elmariah S, Rengifo-Moreno PA, Margey R, O'Callaghan C, Cruz-Gonzalez I, Baron S, Mehrotra P, Tan TC, Hung J, Demirjian ZN, Buonanno FS, Ning M, Silverman SB, Cubeddu RJ, Pomerantsev E, Schainfeld RM, Dec GW Jr, Palacios IF: Long-term experience and outcomes with transcatheter closure of patent foramen ovale. JACC Cardiovasc Interv 2013, 6:1176-83. 10.1016/j.jcin.2013.06.013
3. Ning MM, Lopez M, Sarracino D, Cao J, Karchin M, McMullin D, Wang X, Buonanno FS, Lo EH: Pharmaco-proteomics opportunities for individualizing neurovascular treatment. Neurol Res 2013, 35:448-56. 10.1179/1743132813Y.0000000213
4. Lopez MF, Sarracino DA, Vogelsang M, Sutton JN, Athanas M, Krastins B, Garces A, Prakash A, Peterman S, Demirjian Z, Inglessis-Azuaje I, Feeney K, Elia M, McMullin D, Dec GW, Palacios I, Lo EH, Buonanno F, Ning M: Heart-brain signaling in patent foramen ovale-related stroke: differential plasma proteomic expression patterns revealed with a 2-pass liquid chromatography-tandem mass spectrometry discovery workflow. J Investig Med 2012, 60:1122-30.
5. Xu W, Dong C, Rundek T, Elkind MS, Sacco RL: Serum albumin levels are associated with cardioembolic and cryptogenic ischemic strokes Northern Manhattan study. Stroke 2014, 45:973-8. 10.1161/STROKEAHA.113.003835
6. Ha CE, Bhagavan NV: Novel insights into the pleiotropic effects of human serum albumin in health and disease. Biochim Biophys Acta 1830, 2013:5486-93.
7. Bruschi M, Candiano G, Santucci L, Ghiggeri GM: Oxidized albumin:the long way of a protein of uncertain function. Biochim Biophys Acta 1830, 2013:5473-9.
8. Kragh-Hansen U1, Minchiotti L, Galliano M, Peters T Jr: Human serum albumin isoforms: genetic and molecular aspects and functional consequences. Biochim Biophys Acta 2013, 1830:5405-17. 10.1016/j.bbagen.2013.03.026
9. Gundry RL1, Fu Q, Jelinek CA, Van Eyk JE, Cotter RJ: Investigation of an albumin-enriched fraction of human serum and its albuminome. Proteomics Clin Appl 2007, 1:73-88. 10.1002/prca.200600276
10. Peters T Jr, Stewart AJ: Albumin research in the 21st century. Biochim Biophys Acta 2013, 1830:5351-3. 10.1016/j.bbagen.2013.05.012
11. Lowenthal MS, Mehta AI, Frogale K, Bandle RW, Araujo RP, Hood BL, Veenstra TD, Conrads TP, Goldsmith P, Fishman D, Petricoin EF III, Liotta LA: Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem 2005, 51:1933-45. 10.1373/clinchem.2005.052944
12. Mehta AI, Ross S, Lowenthal MS, Fusaro V, Fishman DA, Petricoin EF III, Liotta LA: Biomarker amplification by serum carrier protein binding. Dis Markers 2003, 19:1-10. 10.1155/2003/104879
13. Lopez MF, Mikulskis A, Kuzdzal S, Bennett DA, Kelly J, Golenko E, DiCesare J, Denoyer E, Patton WF, Ediger R, Sapp L, Ziegert T, Lynch C, Kramer S, Whiteley GR, Wall MR, Mannion DP, Della Cioppa G, Rakitan JS, Wolfe GM: High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. Clin Chem 2005, 51:1946-54. 10.1373/clinchem.2005.053090
14. Lopez MF, Mikulskis A, Kuzdzal S, Golenko E, Petricoin EF III, Liotta LA, Patton WF, Whiteley GR, Rosenblatt K, Gurnani P, Nandi A, Neill S, Cullen S, O'Gorman M, Sarracino D, Lynch C, Johnson A, Mckenzie W, Fishman D: A novel, high-throughput workflow for discovery and identification of serum carrier protein bound peptide biomarker candidates in ovarian cancer samples. Clin Chem 2007, 53:1067-74. 10.1373/clinchem.2006.080721
15. Kikuchi S, Honda K, Handa Y, Kato H, Yamashita K, Umaki T, Shitashige M, Ono M, Tsuchida A, Aoki T, Hirohashi S, Yamada T: Serum albumin-associated peptides of patients with uterine endometrial cancer. Cancer Sci 2007, 98:822-9. 10.1111/j.1349-7006.2007.00458.x
16. Yadav AK, Bhardwaj G, Basak T, Kumar D, Ahmad S, Priyadarshini R, Singh AK, Dash D, Sengupta S: A systematic analysis of eluted fraction of plasma post immunoaffinity depletion: implications in biomarker discovery. PLoS One 2011,6(9):1-9.
17. Rothblat GH, Phillips MC: High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol 2010, 21:229-38. 10.1097/MOL.0b013e328338472d
18. Zhao Y, Van Berkel TJC, Van Eck M: Relative roles of various efflux pathways in net cholesterol efflux from macrophage foam cells in atherosclerotic lesions. Curr Opin Lipidol 2010, 21:441-53. 10.1097/MOL.0b013e32833dedaa
19. Rosenson RS, Brewer HB, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang X-C, Phillips MC, Rader DJ, et al.: Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 2012, 125:1905-19. 10.1161/CIRCULATIONAHA.111.066589
20. Ha JS, Ha CE, Chao JT, Petersen CE, Theriault A, Bhagavan NV: Human serum albumin and its structural variants mediate cholesterol efflux from cultured endothelial cells. Biochim Biophys Acta 2003, 1640:119-28. 10.1016/S0167-4889(03)00027-2
21. Sankaranarayanan S, de la Llera-Moya M, Drazul-Schrader D, Phillips MC, Kellner-Weibel G, Rothblat GH: Serum albumin acts as a shuttle to enhance cholesterol efflux from cells. J Lipid Res 2013, 54:671-6. 10.1194/jlr.M031336
22. Zhao Y1, Marcel YL: Serum albumin is a significant intermediate in cholesterol transfer between cells and lipoproteins. Biochemistry 1996, 35:7174-80. 10.1021/bi952242v
23. Suarez JI, Martin RH, Calvillo E, Dillon C, Bershad EM, Macdonald RL, Wong J, Harbaugh R, ALISAH Investigators: The Albumin in Subarachnoid Hemorrhage (ALISAH) multicenter pilot clinical trial: safety and neurologic outcomes. Stroke 2012, 43:683-90. 10.1161/STROKEAHA.111.633958
24. Belayev L, Liu Y, Zhao W, Busto R, Ginsberg MD: Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke 2001, 32:553-60. 10.1161/01.STR.32.2.553
25. Krastins B, Prakash A, Sarracino DA, Nedelkov D, Niederkofler EE, Kiernan UA, Nelson R, Vogelsang MS, Vadali G, Garces A, Sutton JN, Peterman S, Byram G, Darbouret B, Pérusse JR, Seidah NG, Coulombe B, Gobom J, Portelius E, Pannee J, Blennow K, Kulasingam V, Couchman L, Moniz C, Lopez MF: Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum. Clin Biochem 2013, 46:399-410. 10.1016/j.clinbiochem.2012.12.019
26. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, Byun J, Vuletic S, Kassim S, Singh P, Chea H, Knopp RH, Brunzell J, Geary R, Chait A, Zhao X, Elkon K1, Marcovina S, Ridker P, John F, Oram JF, Heinecke JW: Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007, 117:746-56. 10.1172/JCI26206
27. Breton CV, Yin F, Wang X, Avol E, Gilliland FD, Araujo JA: HDL anti-oxidant function associates with LDL level in young adults. Atherosclerosis 2014, 232:165-70. 10.1016/j.atherosclerosis.2013.10.034
28. Nelson RW, Krone JR, Bieber AL, Williams P: Mass spectrometric immunoassay. Anal Chem 1995, 67:1153-8. 10.1021/ac00103a003
29. Yassine H, Borges CR, Schaab MR, Billheimer D, Stump C, Reaven P, Lau SS, Nelson R: Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: Potential applications to cardiovascular disease and diabetes. Proteomics Clin Appl 2013, 7:528-40. 10.1002/prca.201200028
30. Deliconstantinos G, Tsopanakis C, Karayiannakos P, Skalkeas G: Evidence for the existence of non-esterified cholesterol carried by albumin in rat serum. Atherosclerosis 1986, 61:67-75. 10.1016/0021-9150(86)90114-0
31. Fielding CJ, Moser K: Evidence for the separation of albumin- and apo A-I-dependent mechanisms of cholesterol efflux from cultured fibroblasts into human plasma. J Biol Chem 1982, 257:10955-60.
32. Curtiss LK1, Valenta DT, Hime NJ, Rye KA: What is so special about apolipoprotein AI in reverse cholesterol transport? Arterioscler Thromb Vasc Biol 2006, 26:12-29. 10.1161/01.ATV.0000194291.94269.5a
33. Huang Y, DiDonato JA, Levison BS, Schmitt D, Li L, Wu Y, Buffa J, Kim T, Gerstenecker GS, Gu X, Kadiyala CS, Wang Z, Culley MK, Hazen JE, Didonato AJ, Fu X, Berisha SZ, Peng D, Nguyen TT, Liang S, Chuang CC, Cho L, Plow EF, Fox PL, Gogonea V, Tang WH, Parks JS, Fisher EA, Smith JD, Hazen SL: An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat Med 2014, 20:193-203. 10.1038/nm.3459
34. Maugeais C1, Braschi S, Ouguerram K, Maugeais P, Mahot P, Jacotot B, Darmaun D, Magot T, Krempf M: Lipoprotein kinetics in patients with analbuminemia. Evidence for the role of serum albumin in controlling lipoprotein metabolism. Arterioscler Thromb Vasc Biol 1997, 17:1369-75. 10.1161/01.ATV.17.7.1369
35. Djoussé L1, Rothman KJ, Cupples LA, Levy D, Ellison RC: Serum albumin and risk of myocardial infarction and all-cause mortality in the Framingham Offspring Study. Circulation 2002, 106:2919-24. 10.1161/01.CIR.0000042673.07632.76
36. Palmieri G, Bergamo P, Luini A, Ruvo M, Gogliettino M, Langella E, Saviano M, Hegde RN, Sandomenico A, Rossi M: Acylpeptide hydrolase inhibition as targeted strategy to induce proteasomal down-regulation. PLoS One 2011, 6:e25888. 10.1371/journal.pone.0025888
37. Kim DS1, Marsillach J, Furlong CE, Jarvik GP: Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease. Pharmacogenomics 2013, 12:1495-515.
38. Landmesser U: High density lipoprotein - should we raise it? Curr Vasc Pharmacol 2012, 10:718-9. 10.2174/157016112803520710
39. Murphy AJ, Westerterp M, Yvan-Charvet L, Tall AR: Anti-atherogenic mechanisms of high density lipoprotein: effects on myeloid cells. Biochim Biophys Acta 1821, 2012:513-21.
40. Riwanto M, Landmesser U: High-density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. J Lipid Res 2013, 54:3227-43. 10.1194/jlr.R037762